<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01375556</url>
  </required_header>
  <id_info>
    <org_study_id>110180</org_study_id>
    <secondary_id>11-AA-0180</secondary_id>
    <nct_id>NCT01375556</nct_id>
  </id_info>
  <brief_title>Genetics of the Acute Response to Alcohol in Social Drinkers</brief_title>
  <official_title>Genetics of the Acute Response to Alcohol in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Background:

      - Previous research has shown that a person s genes can influence how they respond to
      alcohol. But researchers do not yet know all the genes that might be involved.

      Objectives:

      - To identify genes that are related to how non-alcoholic individuals respond to alcohol.

      Eligibility:

      - Healthy people between 21 and 30 years of age who have no history of alcohol or drug
      dependence.

      Design:

        -  The study requires one or two 9-hour visits to the National Institutes of Health
           Clinical Center.

        -  Participants must not take any medicines (except birth-control pills for women) for at
           least 3 days before the visit. They must not drink alcohol for at least 2 days before
           the visit.

        -  Screening includes a medical history, physical exam, and a urine test for drugs of
           abuse.

        -  Participants will be given alcohol over about 2.5 hours. This will have about the same
           effect as having three to four drinks. Frequent breathalyzer tests will check breath
           alcohol level during the infusion.

        -  Before and during the infusion, participants will complete questionnaires about mood and
           feelings. Other tests will study thinking, balance, judgment, and risk-taking. Blood
           samples will be collected four times during the infusion.

        -  Participants will have breakfast at the start of the visit (around 8:00 AM). They will
           have a snack before the start of the alcohol infusion (around 10:45 AM). Lunch will be
           served after the alcohol infusion is complete (around 2:20 PM). After the tests, those
           in the study will have to stay in the Clinical Center until their breath alcohol level
           falls below 0.02%. This can take up to 2.5 hours. A final blood sample will be drawn at
           that time. Participants will not be able to drive themselves home after the study
           visits. Also, they should not take any medicines or operate any machinery for at least 2
           hours after leaving NIH.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Previous research, including our prior studies using the alcohol clamp, has shown substantial
      genetic influences on alcohol pharmacokinetics and pharmacodynamics. While the influence of
      several individual genes on alcohol pharmacokinetics and pharmacodynamics has been examined,
      there has not been a comprehensive evaluation of genetic influences on the pharmacokinetics
      and pharmacodynamics of alcohol in humans.

      Objectives: To evaluate the genetic underpinnings of the pharmacodynamics of alcohol using
      candidate gene analysis of measures of the initial and adaptive acute response to alcohol in
      humans.

      Study Population: Subjects will be 21-30 year-old non-smoking, male and female non-dependent
      drinkers in good health, as determined by medical history, physical exam, and ECG and lab
      tests. Subjects with Axis-I psychiatric diagnoses, including alcohol or substance dependence,
      will be excluded.

      Design: The study will be conducted in two phases. In phase I, 40 subjects (20 with positive
      family history of alcoholism (FHP) and 20 with no family history of alcoholism (FHN)) will
      undergo two ethanol infusion sessions to compare different breath alcohol concentration
      exposures. In one session (Clamp session), participants will be infused with 6% ethanol in
      saline using an individualized infusion profile to achieve and clamp breath alcohol
      concentrations (BrAC) at 60 mg% for 2 hours. In the other session (Oral-mimic session),
      participants will be infused with 6% ethanol and saline using another individualized infusion
      profile to achieve a BrAC-time profile that would be typically obtained after oral
      administration (ascending limb to peak BrAC followed by descending limb). During each
      session, serial BrACs will be obtained, and heart-rate and skin blood flow will be
      continuously recorded. A battery of subjective (self-rating questionnaires) and objective
      measures (psychomotor performance, behavioral disinhibition tasks) will be obtained at
      baseline and two points during the infusion to assess the initial response and adaptive
      response to alcohol. The measures of initial response and adaptive response will be compared
      between sessions to determine which provides greater sensitivity (higher effect size) for
      detecting family history differences.

      In phase II, 160 participants will undergo a one session study. Participants will receive an
      ethanol infusion to achieve the BrAC-time profile (Clamp or Oral-mimic) that provides the
      greater sensitivity to family history of alcoholism in phase I of the study. The same battery
      of subjective and objective measures will be obtained to assess the initial response and
      adaptive response to alcohol. These response measures will be used as endophenotypes for
      examination of genetic association with a set of candidate genes, based on previous clinical
      and pre-clinical studies.

      Outcome measures: Initial response to alcohol and adaptive response to alcohol measures will
      be obtained for a battery of assessments, including subjective ratings of alcohol effects,
      psychomotor performance, behavioral disinhibition tasks and autonomic measures.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>May 26, 2011</start_date>
  <completion_date type="Actual">January 20, 2016</completion_date>
  <primary_completion_date type="Actual">January 20, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Initial response to alcohol and adaptive response to alcohol measures for subjective ratings of alcohol effects, psychomotor performance, behavioral disinhibition tasks and autonomic measures</measure>
  </primary_outcome>
  <enrollment type="Actual">33</enrollment>
  <condition>Alcoholism</condition>
  <condition>Genetics</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ethanol</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        Male and female participants between 21-30 years of age.

        Good health as determined by medical history, physical exam, EKG and lab tests.

        EXCLUSION CRITERIA:

        Current or prior history of any disease, including CNS, cardiovascular, respiratory,
        gastrointestinal, hepatic, renal, endocrine, or reproductive disorders.

        Positive hepatitis or HIV test at screening.

        Current (i.e., in the past year) diagnosis of Axis-I psychiatric illness.

        Current or lifetime diagnosis of alcohol or substance dependence.

        Currently (i.e., in the past year) seeking treatment for alcohol-related problems.

        Non-drinkers (alcohol-na(SqrRoot) ve individuals or current abstainers), or individuals who
        have never consumed more than 4 drinks on at least one occasion.

        Current or prior history of alcohol-induced flushing reaction, including rapid reddening of
        the face, rapid heart rate and breathing, and nausea after 1 or 2 drinks.

        Regular tobacco users will be excluded from the study in order to avoid nicotine withdrawal
        symptoms. Occasional use of tobacco products (up to 20 cigarettes/week, Fagerstrom Test for
        Nicotine Dependence Score less than 4) is acceptable.

        Positive result on urine drug screen or breathalyzer test at screening

        No regular use of medications for the last 3 months. Use of prescription or OTC medications
        known to interact with alcohol within 2 weeks of the study. These include, but may not be
        limited to: isosorbide, nitroglycerine, benzodiazepines, warfarin, anti-depressants such as
        amitriptyline, clomipramine and nefazodone, anti-diabetes medications such as glyburide,
        metformin and tolbutamide, H2-antagonists for heartburn such as cimetidine and ranitidine,
        muscle relaxants, anti-epileptics including phenytoin and phenobarbital codeine, and
        narcotics including darvocet, percocet and hydrocodone. Drugs known to inhibit or induce
        enzymes that metabolize alcohol should not be used for 4 weeks prior to the study. These
        include chlorzoxazone, isoniazid, metronidazole and disulfiram. Cough-and-cold preparations
        which contain anti-histamines, pain medicines and anti-inflammatories such as aspirin,
        ibuprofen, acetaminophen, celecoxib and naproxen, should be withheld for at least 72 hours
        prior to each study session.

        Females must not be pregnant or breast-feeding. Female participants will undergo a urine
        beta-hCG test to ensure they are not pregnant during screening and study visits.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vijay A Ramchandani, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bernstein DP, Stein JA, Newcomb MD, Walker E, Pogge D, Ahluvalia T, Stokes J, Handelsman L, Medrano M, Desmond D, Zule W. Development and validation of a brief screening version of the Childhood Trauma Questionnaire. Child Abuse Negl. 2003 Feb;27(2):169-90.</citation>
    <PMID>12615092</PMID>
  </reference>
  <reference>
    <citation>Bierut LJ, Agrawal A, Bucholz KK, Doheny KF, Laurie C, Pugh E, Fisher S, Fox L, Howells W, Bertelsen S, Hinrichs AL, Almasy L, Breslau N, Culverhouse RC, Dick DM, Edenberg HJ, Foroud T, Grucza RA, Hatsukami D, Hesselbrock V, Johnson EO, Kramer J, Krueger RF, Kuperman S, Lynskey M, Mann K, Neuman RJ, NÃ¶then MM, Nurnberger JI Jr, Porjesz B, Ridinger M, Saccone NL, Saccone SF, Schuckit MA, Tischfield JA, Wang JC, Rietschel M, Goate AM, Rice JP; Gene, Environment Association Studies Consortium. A genome-wide association study of alcohol dependence. Proc Natl Acad Sci U S A. 2010 Mar 16;107(11):5082-7. doi: 10.1073/pnas.0911109107. Epub 2010 Mar 2.</citation>
    <PMID>20202923</PMID>
  </reference>
  <reference>
    <citation>Blekher T, Ramchandani VA, Flury L, Foroud T, Kareken D, Yee RD, Li TK, O'Connor S. Saccadic eye movements are associated with a family history of alcoholism at baseline and after exposure to alcohol. Alcohol Clin Exp Res. 2002 Oct;26(10):1568-73.</citation>
    <PMID>12394291</PMID>
  </reference>
  <verification_date>January 20, 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2011</study_first_submitted>
  <study_first_submitted_qc>June 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2011</study_first_posted>
  <last_update_submitted>May 24, 2018</last_update_submitted>
  <last_update_submitted_qc>May 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2018</last_update_posted>
  <keyword>Alcohol Clamp</keyword>
  <keyword>Pharmacogenetics</keyword>
  <keyword>Family History of Alcoholism</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Healthy Volunteer</keyword>
  <keyword>HV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

